NCT05172622 - Safety, Tolerability, and Pharmacokinetic and Pharmacodynamic Characteristics of JP-2266 in Healthy Subjects | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 24, 2020

Primary Completion Date

August 31, 2022

Study Completion Date

August 31, 2022

Conditions

Diabetes Mellitus

Interventions

DRUG

JP-2266

"* Single Ascending Dose: Single administration on Day 1~* Food effect cohort: Single administration on Day 1 of each period~* Multiple Ascending Dose: Repeated administrations from D1 to D15"

DRUG

JP-2266 Placebo

"* Single Ascending Dose: Single administration on Day 1~* Food effect cohort: Single administration on Day 1 of each period~* Multiple Ascending Dose: Repeated administrations from D1 to D15"

Trial Locations (1)

38610

RECRUITING

OPTIMED clinical research, Gières